Celsion Corporation announced Monday that it will change its name to Imunon.
The clinical-stage drug development biotech said the move is intended to reflect the “evolution of the company’s business focus” as well as its commitment to developing immunotherapies and next-generation vaccines.
This marks a major initiative for Imunon CEO Dr. Corinne Le Goff, who joined the company after previously serving as chief commercial officer at Moderna. There, she was responsible for overseeing the global distribution and commercial strategy for the company’s COVID-19 vaccine.
“With this name change, we are underscoring our commitment to create a new category of medicines leveraging our proprietary plasmid DNA technology platform in the fields of immuno-oncology and vaccines,” Imunon CEO Dr. Corinne Le Goff said in a statement. “With a strong balance sheet supporting current operations into 2025, we are well positioned to build a differentiated company to deliver on the promise of our gene-based therapies.”
The New Jersey-based company’s stock will begin trading under a new Nasdaq ticker symbol on Wednesday.
